BioSpace News Archive

Aimmune Therapeutics, Inc. announced that Jayson Dallas, M.D., President and Chief Executive Officer, will present at the Needham & Company 18th Annual Healthcare Conference on Wednesday, April 10, 2019, at 8:00 a.m. Eastern Time in New York City.

Alliance will enable a faster and more rigorous approach to biomarker discovery and companion diagnostic co-development

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced data demonstrating the potential use of ibrexafungerp as an agent to address multiple serious fungal infections, including many that have shown resistance to existing therapies.

Pharm-Olam was rated highly by small pharma survey respondents, as well as all survey respondents combined, for delivering excellent clinical research services in Compatibility, Quality, and Reliability core award categories.

AMX0035 is Amylyx’s proprietary two-drug combination therapy in development to prevent nerve cell death and degeneration.

Avanos Medical, Inc. (NYSE: AVNS), a company focused on delivering clinically superior medical device solutions to improve patients’ quality of life, announced today that it has received U.S. Food and Drug Administration (FDA) 501(k) clearance for its ON-Q* with Bolus pump.

Compugen Ltd. announced that its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, was featured in a trial-in-progress poster at The 2019 AACR Annual Meeting in Atlanta, GA.

Tribesterone® is a proprietary oral Natural Health Product containing the clinically tested ingredient Tribulus Terrestris and its active constituent, Protodioscin, to support and increase free testosterone levels in adult males.

Sage Therapeutics announced that, on April 1, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 25,190 shares of its common stock, and 865 performance restricted stock units to five new employees under Sage’s 2016 Inducement Equity Plan.

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that it has established a new subsidiary – Canonic Ltd – to develop next generation medical cannabis products.